Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 884 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Coagulation Disorders Clear all
Completed Phase 1 Interventional

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

NCT02941354
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Chicago, Illinois • Peoria, Illinois • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 10, 2026, 1:55 PM EDT
Completed No phase listed Observational

Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial (CAF-PINT)

NCT01892969
View directory record Official record
Conditions
Heart Failure, Respiratory Failure
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
14 Days to 18 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Los Angeles, California • Oakland, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Phase 1 Interventional

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

NCT02407080
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocythemia
Interventions
RG7388, Pegasys
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 10, 2026, 1:55 PM EDT
Not yet recruiting Not applicable Interventional

Study of a Smart Sharps Disposal Device in Patients With Hemophilia

NCT07421154
View directory record Official record
Conditions
Hemophilia A and B
Interventions
The smart Sharps device is given to the patient and they use it to throw needles away in. It is not internal to the patient.
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 10, 2026, 1:55 PM EDT
Completed No phase listed Observational

Inhibitor Development in Patients With Hemophilia A Undergoing Surgery

NCT01571934
View directory record Official record
Conditions
Hemophilia A
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 10, 2026, 1:55 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

NCT06703606
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
MARSTACIMAB
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 74 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Results available

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

NCT02795767
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 17 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 10, 2026, 1:55 PM EDT
Completed No phase listed Observational

A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

NCT01974232
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Months to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Phase 2Phase 3 Interventional

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

NCT01625390
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
BAY86-6150, eptacog alfa [activated]
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 62 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Sacramento, California • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 10, 2026, 1:55 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.

NCT07288489
View directory record Official record
Conditions
Blood Loss, Surgical, Coagulation Disorder
Interventions
VMX-C001, Usual Pharmacological Care
Drug
Lead sponsor
VarmX B.V.
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
17
States / cities
Chandler, Arizona • Phoenix, Arizona • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Phase 1 Interventional

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

NCT01184820
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))
Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 10, 2026, 1:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery

NCT00096590
View directory record Official record
Conditions
Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
coagulation study, immunoenzyme technique, laboratory biomarker analysis, physiologic testing, study of high risk factors
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2009 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

NCT02554773
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Fitusiran (SAR439774)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

NCT00005797
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, Cyclophosphamide, VP-16, Fractionated Total Body Irradiation (FTBI)
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 55 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

NCT04188379
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
efgartigimod, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

NCT02279173
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Romiplostim
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 18 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
16
States / cities
Roseville, California • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 10, 2026, 1:55 PM EDT
Completed No phase listed Observational Results available

Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease

NCT01602419
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Patients using Wilate as standard of care
Other
Lead sponsor
Octapharma
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Torrance, California • Miami, Florida • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 10, 2026, 1:55 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

NCT00076557
View directory record Official record
Conditions
Hemophilia B
Interventions
Adeno-Associated Viral with Human Factor IX
Genetic
Lead sponsor
Avigen
Industry
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Palo Alto, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2007 · Synced Oct 10, 2026, 1:55 PM EDT
Terminated Phase 1 Interventional

Hemophilia B Gene Therapy With AAV8 Vector

NCT01620801
View directory record Official record
Conditions
Hemophilia B
Interventions
AAV8-hFIX19
Biological
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 10, 2026, 1:55 PM EDT
Recruiting Phase 3 Interventional

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Mezagitamab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
25
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Not applicable Interventional

Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

NCT00816127
View directory record Official record
Conditions
Liver Cirrhosis, Coagulopathy
Interventions
Desmopressin, blood transfusion
Drug · Biological
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2009 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

NCT02125318
View directory record Official record
Conditions
Thrombocytosis, Myeloproliferative Neoplasms
Interventions
Anagrelide CR
Drug
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Burbank, California • Encinitas, California • Escondido, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 10, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Eltrombopag at Escalated Doses

NCT01880047
View directory record Official record
Conditions
Immune Thrombocytopenia, Platelet Disorder
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 10, 2026, 1:55 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ataluren (PTC124) in Hemophilia A and B

NCT00947193
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Peoria, Illinois • Indianapolis, Indiana • Worcester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 10, 2026, 1:55 PM EDT